Kaporis Helen G, Guttman-Yassky Emma, Lowes Michelle A, Haider Asifa S, Fuentes-Duculan Judilyn, Darabi Kamruz, Whynot-Ertelt Julia, Khatcherian Artemis, Cardinale Irma, Novitskaya Inna, Krueger James G, Carucci John A
Laboratory for Investigative Dermatology, Rockefeller University, New York, New York, USA.
J Invest Dermatol. 2007 Oct;127(10):2391-8. doi: 10.1038/sj.jid.5700884. Epub 2007 May 17.
Basal cell carcinoma (BCC), the most common human cancer, undergoes spontaneous regression in certain circumstances, which is potentially immune-mediated. To understand the immune response surrounding BCCs, we characterized the genomic, protein, and cellular microenvironment associated with BCC in comparison to normal skin. Our results demonstrated the following: (1) CD4+ CD25+ Foxp3+ surround epithelial tumor aggregates; (2) Immature dendritic cells (DCs) were abundant in the tumor microenvironment; (3) BCC showed increased expression of IL-4, IL-10, and CCL22 and increased expression of interferon-associated genes (IFI27, IRF1, IRF7, and G1P2) and IL-12/23, gene indicating a Th2 dominant microenvironment. Our findings suggest a dynamic state within the immune microenvironment associated with BCC. The finding of phenotypic T regs, in conjunction with immature DCs and Th2 cytokines, suggests an attenuated state of immunity to human BCC. In contrast, abundant CD8+ T cells, an interferon signal, and IL-12/23 suggest partial host antitumor response. A better understanding of these opposing forces within the immune microenvironment may facilitate development of more potent immune-based treatment for BCC and other human carcinomas.
基底细胞癌(BCC)是人类最常见的癌症,在某些情况下会发生自发消退,这可能是由免疫介导的。为了了解围绕BCC的免疫反应,我们将与正常皮肤相比,对与BCC相关的基因组、蛋白质和细胞微环境进行了表征。我们的结果表明:(1)CD4 + CD25 + Foxp3 +细胞围绕上皮肿瘤聚集体;(2)未成熟树突状细胞(DC)在肿瘤微环境中丰富;(3)BCC显示IL-4、IL-10和CCL22的表达增加,以及干扰素相关基因(IFI27、IRF1、IRF7和G1P2)和IL-12/23基因的表达增加,表明是Th2主导的微环境。我们的发现表明与BCC相关的免疫微环境处于动态状态。表型调节性T细胞的发现,连同未成熟的DC和Th2细胞因子,表明对人类BCC的免疫状态减弱。相比之下,丰富的CD8 + T细胞、干扰素信号和IL-12/23表明宿主有部分抗肿瘤反应。更好地理解免疫微环境中这些相反的力量可能有助于开发更有效的针对BCC和其他人类癌症的免疫治疗方法。